KORU Medical Systems (NASDAQ:KRMD - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect KORU Medical Systems to post earnings of ($0.02) per share and revenue of $8.86 million for the quarter.
KORU Medical Systems Price Performance
Shares of NASDAQ KRMD traded down $0.09 during trading hours on Monday, reaching $2.76. 39,745 shares of the stock traded hands, compared to its average volume of 140,611. The company's 50-day simple moving average is $2.69 and its two-hundred day simple moving average is $3.38. The company has a market capitalization of $127.35 million, a P/E ratio of -10.98 and a beta of 0.39. KORU Medical Systems has a 52-week low of $1.86 and a 52-week high of $5.05. The company has a quick ratio of 2.37, a current ratio of 2.99 and a debt-to-equity ratio of 0.01.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. Lake Street Capital lifted their price target on shares of KORU Medical Systems from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday, January 14th. Craig Hallum upped their price target on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a "buy" rating in a research report on Friday, January 17th. B. Riley upgraded KORU Medical Systems to a "strong-buy" rating in a report on Thursday, March 13th. Finally, Piper Sandler restated a "neutral" rating and set a $4.50 target price on shares of KORU Medical Systems in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, KORU Medical Systems has a consensus rating of "Buy" and an average target price of $4.70.
Check Out Our Latest Research Report on KRMD
KORU Medical Systems Company Profile
(
Get Free Report)
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.
See Also
Before you consider KORU Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KORU Medical Systems wasn't on the list.
While KORU Medical Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
